Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Management is intentionally pivoting the company from a legacy equipment leasing model to a diversified radiation oncology platform focused on direct patient services.
Revenue growth of 19% was primarily driven by higher patient volumes in Rhode Island and improved international performance following technology upgrades. The international strategy is yielding results in Peru, where the ESPRIT Gamma Knife upgrade has significantly improved patient throughput and utilization. Proton beam radiation therapy in Orlando remains a key growth driver, benefiting from a combination of increased treatment volumes and favorable reimbursement trends.
Management attributes the current operational success to higher utilization across the network, which they identify as the primary driver of long-term profitability. The company generated $4.4 million in cash from operations in the first half of 2026, which management views as validation of their improved cash-generating capability. The third amendment and forbearance agreement with Fifth Third Bank provides a defined framework to pursue long-term capital solutions through June 2027.
Management is evaluating all options to address the $15.5 million debt obligation, including refinancing or potential asset sales as outlined in the credit agreement. Future growth is centered on the Rhode Island market, specifically advancing plans for a new radiation therapy center in Bristol and a proton beam center in Johnston. International expansion remains a priority, with an upcoming Gamma Knife upgrade at Hospital San Javier in Guadalajara, Mexico, targeting an established clinical market.
The company expects incremental revenue to increasingly translate into improved profitability due to the significant operating leverage inherent in their treatment facilities. A $909 thousand allowance for credit losses was recorded against Rhode Island receivables dating prior to May 2025, stemming from disputes with insurance carriers. The company incurred $285 thousand in legal and professional costs specifically related to negotiating the third amendment to their credit agreement.
Executive Chairman Raymond Stachowiak provided $2 million in subordinated financing post-quarter end to enhance liquidity and financial flexibility. Wallace was appointed Interim CFO following the departure of Scott Raymond Frech to pursue other opportunities. Nvidia-level potential. 30M+ investors trust Moby to find it first.
Extract — continue reading at the source.
